ChickenPox-Varicella vaccine
| Product Overview | |
| Generic Name | ChickenPox-Varicella vaccine |
| Brand Name(s) | VARILRIX (GSK); VARIVAX-III (Merck/MSD); BIO POX (Bio-Med, India) |
| Form | Lyophilised (freeze-dried) powder + diluent for solution/suspension for injection |
| Strength | 1350 PFU per 0.5 mL dose |
| Therapeutic Class | Immunizing agent against varicella (chickenpox). |
| ATC Code | J07BK01 |
| Manufacturing & Regulatory | |
| Manufacturer | MSD, GSK, Biomed |
| Country | India/USA/EU |
| GMP Compliance | WHO-GMP |
| Logistics & Export | |
| MOQ | 100 units |
| Shelf Life | 12 to 24 months |
| Storage | Refrigerated (2–8 °C) |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 4 weeks |
| Documentation | |
| Certificate of Analysis (COA) | Supplied per batch upon request |
Description
Chickenpox (varicella) vaccine is a live attenuated viral vaccine indicated for active immunization against varicella (VZV) in susceptible individuals; commonly administered as a 2-dose schedule from ≥12 months of age per local immunization guidance.
